The Advancing New Mechanisms and Emerging Treatments in Metastatic Castration Resistant Prostate Cancer (mCRPC) application process is still open. Interested candidates are urged to click here to learn more about this opportunity and to apply.
About Advancing New Mechanisms and Emerging Treatments in mCRPC
Opportunity Details
This competitive grant program seeks to support independent medical education addressing the new mechanisms in mCRPC including EZH2 inhibition and its possible role in prostate cancer and the continued unmet need for novel therapies in mCRPC
Benefits of Advancing New Mechanisms and Emerging Treatments in mCRPC
- Individual projects requesting between $75,000 - $250,000 will be considered. The estimated total available budget related to this RFP is $500,000.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
Advancing New Mechanisms and Emerging Treatments in mCRPC Requirements
Geographic Scope/Location of Project
- United States and Europe are the priority regions although proposals with global reach are encouraged Applicant Eligibility Criteria
- Applicant organizations to this RFP must be based in the United States or Europe
- The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead’s grant coordinator).
- The project/program lead must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
- For projects offering continuing education credit, the requesting organization must be accredited.
Primary Area of Interest:
- Genitourinary General Area of Interest for this RFP: It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.
- Projects that will be considered for Pfizer support will focus on increasing healthcare professional awareness and understanding in the following areas:
- differentiated mechanism of action (MOA) of emerging therapies including EZH2 inhibition and its possible role in prostate cancer¹
- EZH2 and other novel mechanisms of disease (MOD) and their role in prostate cancer progression² • the investigational thesis of how concomitant EZH2 and AR inhibition may suppress prostate cancer while delaying or overcoming ARPi resistance³
- the continued unmet need for novel therapies in mCRPC
- mCRPC therapies beyond chemotherapy
- ongoing clinical trials that may be an option for patients today
- Examples of educational formats that will be considered under this RFP include but are not limited to:
- On-agenda educational sessions during live conferences
- Multi-company supported, stand-alone symposia
- Expert interviews recorded at live conferences, conference coverage reviews
- Online articles, newsletter articles, training courses, webinars • Social media posted & linked content
- Videos, podcasts, infographics, animations Target Audience
- Oncologists, urologists, oncology nurses and nurse practitioners, physician assistants, pharmacists and other healthcare professionals involved in the care and treatment of people with prostate cancer
Application Date and Process
IMPORTANT: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.
Please go to www.cybergrants.com/pfizer/knowledge and sign in.
- Note: there are individual portals for each grant application type. Please be sure to use the URL above.
- First-time users should click “Create your password”.
- It is strongly suggested to log in before the submission deadline to ensure organization information is up to-date (e.g. prior reporting requirements completed, tax ID number updated, etc.)
- Click the “Start A New Knowledge Gap Application” button.
Requirements for submission:
- Complete all required sections of the online application
- IMPORTANT: Upload proposal (see Appendix) in the General RFP Submission field. In the application:
- For the question “Competitive Grant?” select “Yes”
- Select the following Primary Area of Interest: Oncology- Genitourinary- KG
- Select the following Competitive Grant Program Name: 2025 ONC Global mCRPC New Mechanisms IME
Application Deadline
14 October, 2025
Scholarship Application Portal
View details of
Advancing New Mechanisms and Emerging Treatments in mCRPC
Apply for Advancing New Mechanisms and Emerging Treatments in mCRPC
